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 Review Article 
BUCCAL DRUG DELIVERY SYSTEM: AN OVERVIEW ABOUT 
DOSAGE FORMS AND RECENT STUDIES 
ABSTRACT 
Buccal drugadministarion and delivery has attracted important interest onrecent years 
especially in terms of possibility of buccal administration of already exist medicines 
administered via different routesand as well as to develop various formulations for 
administration of novel pharmaceutical active agents. The advantages of oral mucosahas gain 
importance for local and systemic drug delivery due to its high blood flow, prevention of 
hepatic first-pass effect, rapid recovery and good absorption profile. This review provides 
information about the potential of buccal drug delivery systems, different dosage forms and 
recent studies. 
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INTRODUCTION 
Drug research and development has been progressing in improving the quality of life of 
patients as well as contributing to the treatment of diseases [1,2]. Buccal drug administration 
has remarkable advantages such as prevention of elimination and first-pass effect in the 
gastrointestinal tract, having a more favorable enzymatic environment for the absorption of 
certain drugs, easy to administer to pediatric, geriatric patients and patients with intellectual 
disabilities and having low cost. [2-4] The oral mucosa is highly vascularized, drugs absorbed 
through the mucosa bypass the first-pass metabolism and enter the systemic circulation 
directly. Furthermore, the high blood flow and permeability of the oral mucosa makes it an 
ideal site of administration for the rapid systemic delivery of a drug in the treatment of pain, 
seizures and angina pectoris [6-7]. When transmucosal drug administration routes are 
compared among themselves, buccal route is prominent with patient compliance. Rectal and 
vaginal delivery systems are in part less acceptable ways for patients. In terms of drug 
administration, rectal and vaginal administration may sometimes lead to slow and sometimes 
incomplete drug absorption and may vary in the same person or between individuals [5]. For 
nasal application; The limited area of the nasal cavity, the rapid removal of the administered 
drug, and the variable physiological functions of the nasal cavity are among the disadvantages 
of this application. [7].  
With the development of mucoadhesive formulations, the local and systemic effects of drug 
delivery systems have increased. The likelihood of using biological agents such as genes, 
peptides and antibodies that can be reduced by the administration of oral mucosa may 
increase [7,8]. Pharmaceutical researchers are conducting further research on the development 
of novel drug delivery systems to enhance the therapeutic effects of existing molecules 
relative to novel drug molecules. At this point, buccal drug systems are thought to have great 
potential and this review summarizes general information about buccal drug delivery systems 
and provides information about recent studies. 
Anatomical Structure of Oral Cavity 
The oral cavity consists of the lips, cheeks, tongue, hard palate, soft palate and the base of the 
mouth, and its surface consists of oral mucosa (Figure 1). Oral mucosa; buccal, sublingual, 
gingival, palatal and labial mucosa, buccal mucosal tissues (buccal), the bottom of the mouth 
(sublingual) and the ventral surface of the tongue accounts for about 60% of the oral mucosal 
surface area (Figure 2) [9]. Buccal and sublingual tissues are a suitable site for oral mucosal 
administration and these are the regions with the highest permeability in the oral mucosa [10]. 
The epithelium of the oral cavity resembles the skin epithelium, but exhibits distinct 
characteristics from the skin in terms of keratinization, protective and lubricating mucus. 
Mucus is a translucent and viscous secretion that forms a thin and continuous gel layer that 
 adheres to the mucosal epithelial surface. Generally, mucus components; water (95%), 
glycoproteins and lipids (0.5-5%), mineral salts (1%) and free protein (0.5-1%). The salivary 
glands produced by the salivary glands in the oral cavity and as part of the saliva, mucus 
secreted from the major and minor salivary glands are present, allowing the adhesion of 
mucoadhesive drug delivery systems during drug administration [11,12]. 
 
 
Figure 1. Schematic representation of the different linings of mucosa in mouth [9]. 
 
Figure 2. Structure of the oral mucosa [9]. 
 
The Advantages and Disadvantages of Buccal Drug Administration  
The buccal area has a highly vascularized tissue and a neutral environment. The route of 
drugs through the buccal mucosa is like a slow i.v. infusion. Thus higher bioavailability of 
some medicines may be achieved with less doses compared to conventional oral dosage 
forms. Absorption, the size of the drug molecule, its sensitivity to hydrophilicity, its 
enzymatic degradation, and its application to the oral cavity need to be taken into 
consideration to accomplish the above mentioned achievement [13-15].The advantages and 







Table 1. The advantages and disadvantages of buccal drug delivery [16]. 
Advantages of buccal drug delivery Disadvantages of the buccal drug delivery 
 
 Easy application and termination of dosage 
form. 
 The drug remains in the oral cavity for a 
long time. 
 It is applicable to pediatric, geriatric and 
unconscious patients. 
 Drugs can be protected from the first-pass 
metabolism. 
 Higher bioavailability of drug can be 
achieved. 
 Allows lower doses and decrease side 
effects. 
 Permeability is higher than in skin. 
Therapeutic serum concentrations of the 
drug can be achieved more rapidly. 
 Since enzymatic activity is prevented, the 
active agents such as peptides, proteins 
and ionized forms  can be incorporated to 
buccal dosage forms. 
 
 Drug administration via this route has certain 
limitations. 
 Drugs that are irritant, having unpleasant taste 
or odor is not suitable. 
 Drugs that are unstable at buccal pH cannot 
be administered. 
 Only drugs with a small dose requirement can 
be administered. 
 Only drugs that are absorbed by passive 
diffusion can be administered.Drugs that have 
passed into swallowed saliva follow the 
peroral route need to be consider. 
 Hydration may result in the unwanted 
deformation of buccal dosage form.  
 The buccal mucosa is less permeable than the 
small intestine, rectum, etc. Surface area 
available for absorption is less. 
Possibility of swallowing of the buccal dosage 





BUCCAL DOSAGE FORMS AND APPLICATIONS 
Numerous different dosage forms are available for buccal administration, such as tablets, 
films, lozenges, sprays, gels, lollipops, gums and powders. In addition, new formulations such 
as sponges can be used for buccal drug administration [17,18]. Various types of buccal dosage 
forms are presented below Figure 3 [19]. 
Buccal dosage forms include dry dosage forms that need to be moistened before buccal tablets 
are administered [12]. In recent years, various mucoadhesive buccal tablet formulations have 
been prepared by direct compression for local or systemic effect. Buccal tablets can be 
developed to release the active ingredient into the saliva either unidirectionally or 
multidirectionally by targeting the buccal mucosa [18]. The buccal films / patches comprise 
an impermeable layer of the active substance / formulation, a reservoir layer containing the 
formulation in which the active substance is released in a controlled manner, and a 
mucoadhesive surface for attachment to the mucosa. Compared to creams and ointments, they 
are more advantageous in delivering a certain dose of the drug to the site [20]. Buccal films 
are more preferred than buccal tablets. Because buccal tablets are more flexible and can be 
applied more easily. In addition, they can reduce pain by protecting the wound surfaces and 
improve treatment efficacy [21].Buccal films are particularly designed for pediatric patients 
[22]. 
Buccal gels and ointments are semi-solid dosage forms and have the advantage of easy 
administration to the buccal mucosa. The problem of low adhesion of the gels in the field of 
application was overcome by the preparation of mucoadhesive formulations [2]. Buccal gels 
or ointments are less preferred by patients than buccal tablets and films, but are generally 
administered for local effect [12]. 
  
 
Figure 3. Various types of buccal dosage forms [19]. 
 
Buccal dosage forms may be developed for systemic effect or for local treatment of the oral 
mucosa. When selecting the dosage form, the target site of action and the properties of the 
active substance should be considered [23]. For mucosal and transmucosal administration, 
conventional dosage forms cannot provide therapeutic drug levels in the mucosa and 
circulation due to the physiological nature of the oral cavity (the presence of saliva and the 
effect of mechanical stress). The constant flow of saliva and the mobility of tissues within the 
mouth makes it difficult to keep the dosage form in the oral cavity. The residence time of 
medications administered to the oral cavity is generally between 5 and 10 minutes. Since the 
dosage form remains in the absorption area for a very short time, an unpredictable distribution 
is observed. In order to achieve the desired therapeutic effect, it is important to increase the 
contact time between the formulation and the mucosa. For this purpose, mucoadhesive buccal 
formulations are developed using mucoadhesive polymers. To develop an ideal mucoadhesive 
buccal drug delivery system, it is important to identify and understand the forces responsible 
for adhesive bond formation [24]. There are three sites that are effective for the formation of 
adhesive bonds between the polymer and mucus: 
 
 Surface of bioadhesive material 
 First layer of mucosa 
 Interface between mucosa and bioadhesive material 
 The adhesion mechanisms of polymers to mucosal surfaces have not yet been fully 
understood. However, various theories such as adsorption theory, wetting theory, electrical 
theory, diffusion theory and fracture theory have been proposed[11,25]; 
In particular, buccal systems are needed to treat local diseases of the mucosa [24,26]. In order 
to provide therapeutic requirements, buccal dosage forms include; penetration enhancers to 
increase the permeability of the active substance by transmucosal administration or mucosal 
administration; enzyme inhibitors to protect the active substance from degradation by mucosal 
enzymes. Due to the limited absorption area with respect to the site of administration of the 
buccal dosage form, they are generally preferred for a buccal delivery system of 1-3 cm
2
 and 
for active ingredients with a daily dose of 25 mg or less. The ellipsoidal shape is most 
preferred in films / patches and the thickness of buccal drug delivery systems is generally 
limited to a few millimeters [27]. Many diseases can affect the thickness of the buccal 
epithelium and ultimately alter the barrier property of the mucosa. Some diseases or 
treatments may also affect mucus secretion and properties [11]. Due to these 
physiopathological conditions, changes in the mucosal surface may make it difficult to 
administer and retain a buccal delivery system. Therefore, it is necessary to evaluate the 
structure of the mucosa under the relevant disease conditions in order to develop an effective 
buccal release system. In addition, it should be noted that active substances that have the 
potential to alter the physiological conditions of the oral cavity may not be suitable for buccal 
administration [27]. 
RECENT STUDIES AND ON BUCCAL DRUG DELIVERY AND FUTURE 
APPROACHES 
Pather et al. summarized challenges for the development and approval of buccal dosage forms 
and they briefly summarized them as; including low dose drugs, biology and permeability 
issues and the complexity of them, need a special mechanismto enhance the absorption of the 
drug without causing undue side effects, the taste of the drug and patient acceptability, dose 
titration for in vivo studies may prove to be difficult,  
difficulties related with regulations, authorities and economical circumstances [28] 
The major obstacle to the use of many hydrophilic macromolecules is inadequate and 
irregular oral absorption. With the development of recombinant DNA technology, buccal 
administration is thought to be important in order to develop protein and peptide formulations 
in the future and deliver them to the systemic circulation by a non-parenteral administration 
[26]. In line with recent developments in buccal drug delivery systems such as lipophilic gel, 
buccal spray and phospholipid vesicles, numerous studies have been conducted on the buccal 
administration of peptides. In particular, some researchers have proposed the use of glyceryl 
monooleate phases of cubic and lamellar liquid crystals as buccal drug delivery systems for 
peptide-structured drugs [29]. Some researchers have developed liquid crystal systems for the 
buccal administration of KSL-W, an antimicrobial decapeptide to treat multispecific oral 
biofilms [30]. In addition, a new insulin liquid aerosol formulation has been developed. This 
formulation has been shown to allow metered dose insulin administration in the form of 
aerosolized droplets for buccal administration. Compared to conventional dosage forms, a 
significant increase in the level of the active ingredient has been shown in the buccal dosage 
form. Studies have shown that this oral aerosol formulation is rapidly absorbed from the 
buccal mucosa and provides the necessary postprandial plasma insulin levels in diabetic 
patients. This new, painless, oral insulin formulation; rapid absorption, an application 
technique with high patient compliance and full dosing have been reported to have many 
advantages [31]. Another interesting novel buccal formulation used gold nanoparticle 
technology to form a film soluble in buccal mucosa. Clinical trials have been reached in two 
approaches to insulin buccal administration: oromucose sprays of the peptide, a permeability 
enhancing film, and gold nanoparticles embedded in a soluble film [32,33].  
 In another study, soy lecithin and propanediol were used for insulin buccal spray formulation. 
Soy lecithin has a high affinity for biological membranes, but its solubility is low and the 
solubility of propandiol and soy lecithin could be increased. Insulin buccal spray was applied 
to diabetic rabbits and the hypoglycemic effect of the formulation was investigated. When the 
results were examined, it was shown that there was a significant decrease in blood glucose 
levels of rabbits treated with insulin buccal spray compared to the control group. To 
investigate insulin delivery from the buccal mucosa, the distribution of fluorescence probe in 
the epithelium using confocal laser scanning microscopy and fluorescence probe 
isothiocyanate-labeled insulin penetration were examined. The results demonstrated that the 
fluorescent probe isothiocyanate-labeled insulin can pass through the buccal mucosa, and that 
insulin passes through the epithelium, which includes both intracellular and paracellular 
pathways [34]. The world's first approved transbuccal release system for testosterone 
replacement therapy in men is a mono-convex, tablet-like mucoadhesive buccal system, with 
a recommended dose of 30 mg at a 12-hour interval. This transbuccal delivery system is 
presented as an alternative to patches, gels or injectable testosterone formulations [21,35]. 
Biodegradable mucoadhesive drug technology has been developed to provide both local and 
systemic effects of drugs in mucosal tissues, and includes a small disc with biodegradable 
layers that enable rapid release of the active ingredient over a period of time. This disc 
adheres to the buccal mucosa and transmits the active ingredient to the mucosa while eroding 
in the mouth [36]. Transmucosal administration is also thought to provide significant benefit 
in the application of new classes of biological drugs, such as nucleic acids, antibodies, and 
proteins [26].A recent study was showed succeded results which wereaimed to design and 
evaluate zolpidem nanoparticle-impregnated buccal films for the treatment of insomnia with a 
prolong drug action. Zolpidem-loaded PLGA nanospheres were succeded in vitro and in vivo 
tests.  [37]. In another recent study it was shown that nabumetone, nonsteroidal anti-
inflammatory drug, including buccal films were prepared using polymers like HPMC, 
Eudragit, sodium alginate, and sodium CMC in varying proportions were subjected to in vitro 
quality control parameters ex-vivo permeation and stability studies and the formulations 
showed optimum results and good control over dug release along with correlation between in-
vitro and ex-vivo studies [38].  
Although there are many formulation studies have been reported in the literature, particularly 
to improve retention and absorption in the buccal and sublingual regions, very few of them 
have translated to the clinical phase. This is because it needs to be a clear benefit of efficacy 
and/or safety with any new drug formulation compared to clinically available dosage forms 
[39]. In addition, comprehensive evaluations of the pharmacokinetics, stability, efficacy, and 
safety of the formulations are required in appropriate animal models as well as in clinical 
studies, based on regulatory standards and protocols. [40] 
Gilhotra et al. has overwieved mucoadhesive buccal drug delivery systems in terms of a 
clinical perspective and studies have shown that buccal drug delivery will be increase for the 
treatment of cardiovascular diseases, migraine, epilepsy and antimicrobial, anti-inflammatory, 
hypoglycaemia, muscle relaxation, emesis concomitant chemotherapy, smoking deterrent 
therapies and also for protein and hormone delivery  [41]. An ongoing clinical studies a 
buccal film study has begun ion April 13 2019 for the treatment of epilepsy as diazepam 
containing buccal film [42].   
Nanoparticulate systems have been incorporated into various dosage forms for buccal drug 
delivery, including gels [43], sprays [44], tablets [45,46], films [47,48,49] and patches [50]. 
These nanoparticulate formulations have been shown to: (i) improve drug permeability across 
the epithelium; (ii) modify drug release kinetics (e.g., controlled release or sustained release); 
(iii) provide solubilization (i.e., to deliver compounds which have physicochemical properties 
that strongly limit their aqueous solubility); and/or (iv) protect compounds that are sensitive to 
 degradation (e.g., peptides). These factors all aim to promote higher sublingual or buccal 
bioavailability of drugs for subsequent systemic absorption [39,51]. 
 
CONCLUSION 
The buccal mucosa provides many advantages for local and systemic drug administration. 
Buccal drug administration is an important field of research as it allows for systemic 
administration of drugs with low oral bioavailability. It is also a suitable alternative in the 
delivery of peptides and protein-structured drugs. Pediatric population still great need of 
developing flexible and appropriate drug dosage forms, it is expected to develop new and 
more buccal dosage forms especially designed for pediatric applications that can improve 
transepithelial drug permeability and improve existing therapies and allow new forms of 
treatment. 
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